Navigation Links
US Oncology Reports 2009 Fourth Quarter and Year End Operating Results
Date:2/25/2010

ays evidence-based care guidelines. A recent study conducted by Aetna and US Oncology, as published in the January 2010 issue of the peer-reviewed Journal of Oncology Practice, demonstrated a 35% savings in direct care costs (chemotherapy treatments, supportive care drugs, emergency room visits, and chemotherapy-related hospital admissions) for non-small cell lung cancer patients treated according to Level I Pathways while maintaining the same life expectancy. The study suggests that adherence to Level I Pathways can reduce costs and create greater value for patients, while producing approximately a thirty percent return on investment for employers and managed care companies by dramatically lowering cost of care.

We are also committed to advancing our network's interaction with patients in addition to the care provided through our 496 sites of services. An example of this commitment is our ongoing development of a patient portal that will offer patients access to their medical records, online bill-pay and appointment scheduling; education about their disease and treatments; and social interaction with other patients and caregivers. We recently acquired two patient education organizations, Cure Media Group and NexCura, to accelerate the portal development and broaden our clinical resources.

CURE Media Group's flagship product, CURE magazine, is focused on providing cancer patients with vital information that will help them make key decisions in their treatment and quality of life. Its current circulation of
'/>"/>

SOURCE US Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. US Oncology Announces Expanded Educational Resources to Cancer Patients Through New Affiliations with CURE & NexCura
2. Roseville Radiation Oncology Center (ROC) Redefines Efficiency With Elekta VMAT Radiotherapy Treatments
3. CURE Magazine Joins US Oncology
4. US Oncology Honored by Texas Governor Perrys Office with Inaugural Governors Business Hall of Fame Award
5. What to Look for When Selecting an Electronic Health Record for Your Community Oncology Practice - Free Educational Webinar
6. Annals of Surgical Oncology adds new society affiliation
7. Review and approval of oncology and hematology drugs at FDA from 2005 to 2007
8. Statement from RC Cancer Centers Regarding News Story on Radiation Oncology
9. Oncology Industry Veteran, Joe Baffone, Joins onPoint Oncology, LLC.
10. New Field of Cardio-oncology Suggested
11. Call for End of Year Donations to the US Oncology Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 Save On ... tech accelerator program in Tampa. Healthbox Florida has ... healthcare companies grow and achieve their goals. , ... 16th, at their launch event at the Mahaffey Theater ... , Co-founder Matt Schneider commented on the Save On ...
(Date:8/28/2014)... Commercial growers all over the continent are waitlisted to ... lights, which perform on par with 1000w HPS at 65% ... needs no cooling equipment and does not overheat the space, ... in that they never need bulbs changed, the internal ROI ... , For many indoor growers, cooler room temperatures also has ...
(Date:8/28/2014)... candidate Ebola vaccine could be given to healthy volunteers ... as September, as part of an series of safety ... that has killed more than 1,400 people in the ... this candidate vaccine, being co-developed by the US National ... accelerated with funding from an international consortium in response ...
(Date:8/28/2014)... repairing nerves with adhesives, most researchers place glue directly ... fix the nerve ends well and allows glue to ... cylindrical. However, it is difficult to insert the nerve ... and there is frictional resistance. Xiangdang Liang and co-workers ... special conduit for the adhesive technique and defined the ...
(Date:8/28/2014)... (Aug. 28, 2014) A subset of patients with ... treated with irinotecan-based therapy, according to a new study ... official journal of the American Gastroenterological Association. , When ... leucovorin adjuvant irinotecan therapy improved overall survival rates ... CIMP is seen in about 10 to 20 percent ...
Breaking Medicine News(10 mins):Health News:Save On Medical Accepted Into Healthbox Accelerator Program 2Health News:New Kind K5 Series LED Grow Lights Pave Way for Future of Indoor Gardening 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Drug shows promise for subset of stage III colon cancer patients 2
... using small impulses of electricity. This innovative device is ... // (TENS) technology, which has long been used by ... pain. ,The device comes in the form of a ... in the air from the snoring sound. ,Sensors ...
... scientists have developed a test that can detect the Hepatitis ... by Arieh Yaari of Soroka University Medical Centre // ... people without kidney functions whose blood must be passed through ... SciDev Net. ,Such patients have a high incidence of ...
... British Cardiac Society, the British Hypertension Society, Diabetes ... // and the Stroke Association have collaboratively ... attacks, stroke and hardening of leg arteries. The ... of developing heart attacks by properly maintaining one’s ...
... cannot be cured by taking medications reports a study ... review of eight // clinical trials that complementary and ... occur after alcohol consumption. Some of the common hangover ... diarrhea, dizziness, fatigue, depressed, poor memory. ,Though, ...
... Health experts in the United States fear that if the deadly ... risk since they are vulnerable // to the H5N1 virus. ... 70 lives in Asia and has appeared in parts of Europe ... slaughtered in an effort to contain the virus. However, experts fear ...
... study conducted at Oregon Health & Science University and ... that a perfect molecular mixture present in male-emitted pheromone ... and increased aggression) dictates the sexual behavior of other ... interest. ,The researchers argue that release of ...
Cached Medicine News:Health News:The Chemistry Of Sexual Attraction Between Male And Female Elephants 2
(Date:8/28/2014)... , August 28, 2014 ... Market Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, ... Growth, Trends and Forecast, 2014 - 2020" the global ... billion in 2013 and is expected to grow at ... reach an estimated value of USD 5.3 billion in ...
(Date:8/28/2014)... 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... FDA clearance for and commercializing its CE Marked ... in identifying children, adolescent, and young adult patients in ... appendicitis, today announced it will present at three upcoming ... Annual Global Investment Conference being held in ...
(Date:8/28/2014)... 2014 Telik, Inc. (OTCQB: TELK), a ... with MabVax Therapeutics, Inc. on July 8, 2014, ... to the development of its lead antibody program ... the Company,s internally developed antibody discovery platform.  These ... antibody based therapeutic and diagnostic products based on ...
Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
... traits contribute to risk, of skin cancer; findings will ... May 18 In two papers published,today, deCODE scientists ... the company,s recent findings in the genetics of pigmentation,traits ... of these,common variants also confer risk of two types ...
... Annual Meeting Will Further Demonstrate, the Strength ... CAMBRIDGE, Mass., May 16 Millennium Pharmaceuticals,The Takeda Oncology ... are scheduled to be featured at the 2008 American ... May 30 -,June 3, 2008. The data will highlight ...
Cached Medicine Technology:deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 2deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 3deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
The EZY Close post op shoe's flap-on-flap closure provides a secure fit and can accommodate even the bulkiest of dressing. Perfect for older patients with limited hand dexterity....
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure....
... who experience severe plantar fasciitis pain, the ... fibrous tissue that can occur after rest ... in the morning. The continuous tension and ... plantar fasciitis and helps stretch the Achilles ...
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Medicine Products: